In study data presented at the 2019 ACR Annual Meeting, researchers evaluated the overall safety of upadacitinib as monotherapy and combination therapy with background disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis.
Researchers assessed the most recent safety data of synthetic and biologic disease-modifying antirheumatic drugs to inform the 2019 update of the European League Against Rheumatism recommendations for the management of rheumatoid arthritis.
Researchers aimed to determine the association of antibiotic usage and rheumatoid arthritis diagnosis and flares.
Investigators identified risk factors for repeat surgical intervention after initial arthrotomy for presumed septic arthritis of the hip.
Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.
Attaining low RA disease activity may reduce risk for serious infections.
Discontinuing methotrexate for 2 weeks following flu vaccine may improve the immunogenicity of the vaccine in patients with rheumatoid arthritis.
The objective of the study was to evaluate initial serologic responses to the 13-valent protein-conjugated and the 23-valent polysaccharide pneumococcal vaccine.
Temporary cessation of methotrexate after receiving the influenza vaccine improves the immunogenicity of vaccination in patients with rheumatoid arthritis.
Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients with rheumatic symptoms.
